Delta-Fly Pharma Inc Is Granted Orphan Drug Designation By Us Food And Drug Administration For Dfp-10917
Delta-Fly Pharma, Inc.Announces That Dfp-10917, A Leading Pipeline Of The Company, Is Granted Orphan Drug Designation (Odd) By Us Food And Drug Administration (Fda) For The Treatment Of Acute Myeloid Leukemia (Aml).Be Given To Odd, Delta-Fly Pharma, Inc. Can Be Entitled To Seven Extra Years Of Marketing Exclusivity And Receive Some Benefits Such As R&D Rebate By Getting Approval.Dfp-10917 Is An Anti-Cancer Agent In Development For The Treatment Of Patients With Refractory/Relapsed Aml. A Phase 3 Clinical Study Has Been Underway At Md Anderson Cancer Center In Texas And Other Major Sites Of Hematologic Cancer Treatment In Usa. The Company Expects To Complete The Patients
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!